Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SkinBioTherapeutics ( (GB:SBTX) ) has shared an announcement.
SkinBioTherapeutics has issued 129,736 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 22 January 2026. Following this modest equity issuance, the company’s total shares in issue will rise to 258,779,463, a change that slightly increases its equity base and voting rights denominator for shareholders under FCA disclosure rules but does not materially alter its operational strategy or market positioning in the skin health sector.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) despite strong revenue growth and a relatively conservative balance sheet. Technicals are supportive due to positive momentum, but overbought signals temper that strength. Valuation remains challenging because losses make the P/E less meaningful and no dividend yield is available.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix platform originating from the University of Manchester. Its business targets the skin healthcare market via five pillars, with the most advanced being cosmetic skincare, developed in partnership with Croda under the Zenakine trade name, and AxisBiotix-branded food supplements leveraging the gut-skin axis to address inflammatory skin conditions, sold direct-to-consumer, via Amazon and through selected Superdrug stores. The group is also pursuing a consolidation strategy, acquiring complementary skincare and cosmetic businesses to expand distribution, geographic reach and manufacturing capacity, and has been listed on AIM since April 2017.
Average Trading Volume: 1,350,232
Technical Sentiment Signal: Buy
Current Market Cap: £50.14M
Find detailed analytics on SBTX stock on TipRanks’ Stock Analysis page.